49.45
-0.20
(-0.40%)
At close: 2:36:11 PM GMT+8
Key Executives
Amounts are as of -- and compensation values are for the last fiscal year ending on that date. Pay is salary, bonuses, etc. Exercised is the value of options exercised during the fiscal year. Currency in TWD.
| Name | Title | Pay | Exercised | Year Born |
|---|---|---|---|---|
| Dr. Kai-Min Chu M.D., Ph.D. | Chairman & CEO | -- | -- | -- |
| Ms. Tzu-Wen Chen | Director of Finance & Accounting Supervisor | -- | -- | -- |
| Mr. Cheng-Hui Hsiung Ph.D. | Chief R&D Officer & Vice GM | -- | -- | -- |
| Ting Yi Chiang | Vice Chief R&D Officer and Director of Clinical Trial R&D Department | -- | -- | -- |
Sinew Pharma Inc.
C516, Building C
No. 99, Ln. 130 Sec. 1, Academia Rd. Nangang Dist.
Taipei, 11571
Taiwan
- Sector:
- Healthcare
- Industry: Biotechnology
- Full Time Employees:
- 51
Description
Sinew Pharma Inc., a biopharmaceutical company, focuses on the development and sale of drugs for the treatment of hepatotoxicity-free acetaminophen and fatty liver diseases. The company's products include SNP-610 drug, which is in Phase II clinical trial for treating patients with non-alcoholic steatohepatitis in Taiwan; and SNP-630, a pre-clinical drug for treating patients with non-alcoholic steatohepatitis. It is also developing SNP-810 for use in analgesic and antipyretic indications; and SNP-830 and SNP-840, which are used as hepatotoxicity-free analgesic medicines in the United States. The company was founded in 2014 and is based in Taipei City, Taiwan.
Corporate Governance
Sinew Pharma Inc.’s ISS Governance QualityScore as of N/A is N/A. The pillar scores are Audit: N/A; Board: N/A; Shareholder Rights: N/A; Compensation: N/A.
Corporate governance scores courtesy of Institutional Shareholder Services (ISS) Scores indicate decile rank relative to index or region. A decile score of 1 indicates lower governance risk, while a 10 indicates higher governance risk.
Upcoming Events
Upcoming Events Information Not Available
Recent Events
Recent Events Information Not Available
Related Tickers
4178.TWO StemCyte International, Ltd.
35.15
+1.59%
6586.TWO CHO Pharma, Inc.
50.90
+1.19%
6652.TWO Eusol Biotech Co.,Ltd.
7.77
-0.38%
6610.TWO TWi Biotechnology, Inc.
13.75
+0.73%
6580.TWO TaiRx, Inc.
26.00
+1.96%
4170.TWO VBI
14.10
+0.71%
6744.TWO Feng Chi Biotech Corp.
19.70
0.00%
6945.TWO AP Biosciences Inc
50.80
-3.05%
7814.TWO HORIEN
33.00
-4.76%
7808.TWO BIONET TX Corp
46.00
-1.08%